Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 20,000 shares at $150.99 ($2.9M) on 2018-11-26, disclosed to the SEC on 2018-11-28.
Open-market sale of $2.9M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $150.99 | 800 | $121K | 4.1% |
| 2 | $152.04 | 3,655 | $556K | 18.9% |
| 3 | $152.75 | 1,995 | $305K | 10.3% |
| 4 | $154.07 | 676 | $104K | 3.5% |
| 5 | $155.08 | 2,210 | $343K | 11.6% |
| 6 | $156.20 | 664 |
| $104K |
| 3.5% |
| 7 | $137.92 | 2,329 | $321K | 10.9% |
| 8 | $138.94 | 2,638 | $367K | 12.4% |
| 9 | $140.14 | 700 | $98K | 3.3% |
| 10 | $141.48 | 690 | $98K | 3.3% |
| 11 | $142.45 | 634 | $90K | 3.1% |
| 12 | $143.35 | 859 | $123K | 4.2% |
| 13 | $144.61 | 700 | $101K | 3.4% |
| 14 | $147.09 | 600 | $88K | 3.0% |
| 15 | $148.06 | 250 | $37K | 1.3% |
| 16 | $149.25 | 400 | $60K | 2.0% |
| 17 | $151.56 | 200 | $30K | 1.0% |
| Total | $147.26 avg | 20,000 | $2.9M | 100% |
| Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $4.6M | — | Filing → |